Avoro Capital Advisor LLC recently announced the acquisition of new stake in Marinus Pharmaceuticals Inc. (NASDAQ:MRNS). The institutional investor has increased its shareholding in the Healthcare company by 92.90% to 11.96 million shares with purchase of 5.76 million shares. This fresh investment now brings its stake to 9.79% valued currently at $20.09 million. In addition, Lion Point Capital LP raised its holdings by 4.5 million to 10.87 million shares. And Tavistock Life Sciences Co. (Inve.. has lifted its position by 100.00% or 4.8 million shares – to 9.6 million shares.
With over 2.6 million Marinus Pharmaceuticals Inc. (MRNS) shares trading Monday and a closing price of $1.94 on the day, the dollar volume was approximately $5.04 million. The shares have shown a positive weekly performance of 1.57% and its price on 08/31/20 lost nearly -1.52%. Currently, there are 99.77M common shares owned by the public and among those 82.92M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 9 analysts who have offered their price forecasts for MRNS have a consensus price objective of $5.44. The analysts have set the share’s price value over the next 12 months at a high of $9.00 and a low of $4.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Marinus Pharmaceuticals Inc. stock is 1.40 for the next 12 months. But an upside of 78.44% will see the stock hit the forecast high price target while mean target price for the stock is $5.25.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 100,000 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 2,380 shares.
The top 3 mutual fund holders in Marinus Pharmaceuticals Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and Fidelity Select Port. – Biotechno. Vanguard Total Stock Market Index owns 3.12 million shares of the company’s stock, all valued at over $5.25 million. The company bought an additional 0.31 million shares recently to bring their total holdings to about 2.56% of the shares outstanding. iShares Russell 2000 ETF sold 83538.0 shares to see its total holdings shrink to 1.79 million shares valued at over $3.0 million and representing 1.46% of the shares outstanding. Fidelity Select Port. – Biotechno bought 1.33 million shares to bring its total holdings to over 1.33 million shares at a value of $2.23 million. Fidelity Select Port. – Biotechno now owns shares totaling to 1.09% of the shares outstanding.
Shares of Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) opened at $2.00, up $0.03 from a prior closing price of $1.97. However, the script later closed the day at $1.94, down -1.52%. The company’s stock has a 5-day price change of 1.57% and -24.51% over the past three months. MRNS shares are trading -10.19% year to date (YTD), with the 12-month market performance up to 68.70% higher. It has a 12-month low price of $1.01 and touched a high of $3.50 over the same period. Currently, 2.6 million shares have been traded, compared to an average intraday trading volume of 1.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.14%, -6.12%, and -5.55% respectively.
Institutional ownership of Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) shares accounts for 77.80% of the company’s 99.77M shares outstanding. Mutual fund holders own 5.79%, while other institutional holders and individual stakeholders account for 58.26% and 12.10% respectively.
It has a market capitalization of $213.01M and a beta (3y monthly) value of 1.94. The earnings-per-share (ttm) stands at -$0.99. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.93% over the week and 8.56% over the month.
Analysts forecast that Marinus Pharmaceuticals Inc. (MRNS) will achieve an EPS of -$0.16 for the current quarter, -$0.14 for the next quarter and -$0.56 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.21 while analysts give the company a high EPS estimate of -$0.1. Comparatively, EPS for the current quarter was -$0.26 a year ago. Earnings per share for the fiscal year are expected to decrease by -10.60%, and 25.30% over the next financial year. EPS should grow at an annualized rate of 20.00% over the next five years, compared to 14.50% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Marinus Pharmaceuticals Inc. (MRNS) as a “Strong Buy” at a consensus score of 1.40. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the MRNS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 01, 2020, with the firm’s price target at $6-$9. Cowen coverage for the Marinus Pharmaceuticals Inc. (MRNS) stock in a research note released on July 01, 2020 offered a Outperform rating with a price target of. Craig Hallum was of a view on April 09, 2020 that the stock is Buy, while Oppenheimer gave the stock Outperform rating on December 20, 2019, issuing a price target of. Jefferies on their part issued Buy rating on March 05, 2019.